Login to Your Account



Other News To Note


Tuesday, December 20, 2011
The ALS Therapy Development Institute entered a research agreement with Biogen Idec Inc., of Cambridge, Mass., and UCB Pharma SA, of Brussels, Belgium, to investigate the use of an anti-CD40L antibody as a potential therapy for amyotrophic lateral sclerosis (ALS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription